SynthesisPloS one2013
How methodologic differences affect results of economic analyses: a systematic review of interferon gamma release assays for the diagnosis of LTBI.
Synthesis in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 5 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Interferon-Gamma Release Assay Testing for Latent Tuberculosis Infection: A Health Technology Assessment.Ontario health technology assessment series · 2024Pooled it
- Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis.PLoS medicine · 2021Pooled it
- Disparities in model-based cost-effectiveness analyses of tuberculosis diagnosis: A systematic review.PloS one · 2018Pooled it
- Impact of Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic Review of Study Methodologies.PloS one · 2016Pooled it
- Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations.PharmacoEconomics · 2015Pooled it
- Performance of TB Antigen-Based Skin Tests Amongst Healthcare Workers-Sevagram, India, 2023-2024.Open forum infectious diseases · 2026Article
- Screening of household contacts for TB infection in Cote d'Ivoire.IJTLD open · 2024Article
- The Global Expansion of LTBI Screening and Treatment Programs: Exploring Gaps in the Supporting Economic Evidence.Pathogens (Basel, Switzerland) · 2023Review
- A cost-effectiveness evaluation of latent tuberculosis infection screening of a migrant population in Malaysia.Scientific reports · 2023Article
- Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India.BMJ global health · 2018Article
- Policy and practice of programmatic management of latent tuberculosis infection in The Netherlands.Journal of clinical tuberculosis and other mycobacterial diseases · 2017Article
- Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2017Article
- A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program.BMC public health · 2015Article
- A scoping review of cost-effectiveness of screening and treatment for latent tubercolosis infection in migrants from high-incidence countries.BMC health services research · 2015Article
- Editorial Comment: Cost-Effectiveness Analysis for Prioritization of Limited Public Health Resources - Tuberculosis Interventions in Texas.Frontiers in public health services & systems research · 2014Article
- Gamma interferon release assays for detection of Mycobacterium tuberculosis infection.Clinical microbiology reviews · 2014Review
- An update on granulomatous diseases of the oral tissues.Dental clinics of North America · 2013Review
- Comparison of Interferon Gamma Release Assay and Tuberculin Skin Test for Diagnosis of Latent Tuberculosis in Psoriasis Patients Planned for Systemic Therapy.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
introductionCost effectiveness analyses (CEA) can provide useful information on how to invest limited funds, however they are less useful if different analysis of the same intervention provide unclear or contradictory results. The objective of our study was to conduct a systematic review of methodologic aspects of CEA that evaluate Interferon Gamma Release Assays (IGRA) for the detection of Latent Tuberculosis Infection (LTBI), in order to understand how differences affect study results.
methodsA systematic review of studies was conducted with particular focus on study quality and the variability in inputs used in models used to assess cost-effectiveness. A common decision analysis model of the IGRA versus Tuberculin Skin Test (TST) screening strategy was developed and used to quantify the impact on predicted results of observed differences of model inputs taken from the studies identified.
resultsThirteen studies were ultimately included in the review. Several specific methodologic issues were identified across studies, including how study inputs were selected, inconsistencies in the costing approach, the utility of the QALY (Quality Adjusted Life Year) as the effectiveness outcome, and how authors choose to present and interpret study results. When the IGRA versus TST test strategies were compared using our common decision analysis model predicted effectiveness largely overlapped. IMPLICATIONS: Many methodologic issues that contribute to inconsistent results and reduced study quality were identified in studies that assessed the cost-effectiveness of the IGRA test. More specific and relevant guidelines are needed in order to help authors standardize modelling approaches, inputs, assumptions and how results are presented and interpreted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.